enfortumab vedotin (Padcev)

Indications

• locally advanced or metastatic urothelial cancer (bladder cancer) unresponsive to previous treatment

Adverse effects

• most common
  • fatigue (50%)
  • alopecia (49%)
  • decreased appetite (44%)
• other
  • rash (48%)
  • peripheral neuropathy (50%)
  • hyperglycenia (11%)

• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• targets nectin-4

More general terms

• antineoplastic monoclonal antibody

Additional terms

• bladder cancer